POSTER #Sa1561

Influence of social determinants of health on advanced therapy initiation in patients with inflammatory bowel diseases in the US

Brown J, Sindaco M, Munshi K, Imeri H, Gravlee E, Barfield E, Siegel CA (presenting author)

Health Disparities

May 2, 2026

12:30 PM – 1:30 PM CT

McCormick Place - Poster Hall, Level 3, Hall F2

POSTER #Su1627

Efficacy and safety of intravenous vedolizumab in pediatric patients with moderate-to-severe ulcerative colitis: Results from the KEPLER Phase 3 trial

Turner D, Kierkus J, Korczowski B, Strisciuglio C, Chen J, Takaki Y, Szakos E, Arumugam R (presenting author), Rizvi A, Yoon M, Campagne O, Angellotti E, Candela N, Velazco N

Uncontrolled Trials and Observations: Biologics

May 3, 2026

12:30 PM – 1:30 PM CT

McCormick Place - Poster Hall, Level 3, Hall F2

POSTER #Su1639

Dual targeted therapy with vedolizumab and tofacitinib in patients with ulcerative colitis: Initial results from the Phase 4 ExiGem study

Yarur A (presenting author), Deepak P, Barnes EL, Ha C, Hudesman D, Jairath V, Lukin DJ, Rubin DT, Schreiber S, Gower M, Jones S, Robinson I, Sanchirico M, Yajnik V

Uncontrolled Trials and Observations: Biologics

May 3, 2026

12:30 PM – 1:30 PM CT

McCormick Place - Poster Hall, Level 3, Hall F2

POSTER #Su1644

Persistence and treatment patterns of patients with inflammatory bowel disease switching from vedolizumab intravenous to subcutaneous maintenance therapy: Data from a Canadian cohort

Horst SN (presenting author), Moulson R, Yang Z, Pettengell C, Brown J, Barfield E, Gift T, Liu Y, Power GS, Bressler B

Uncontrolled Trials and Observations: Biologics

May 3, 2026

12:30 PM – 1:30 PM CT

McCormick Place - Poster Hall, Level 3, Hall F2

POSTER #Mo1517

Evaluation of transmural healing in patients with moderately to severely active Crohn's disease shows early efficacy of vedolizumab: VECTORS Week 14 interim analysis

Jairath V (presenting author), Vuyyuru SK, Ma C, Zou GY, Neustifter B, Agboton C, Romo Bautista I, Wu JJ, Jiang J, Allocca M, An Y-K, Begun J, Bryant RV, Danese S, Dubinsky M, Freire M, Novak KL, Panaccione R, Pudipeddi A, Rubin DT, Sands BE, Sparrow M, Taylor SA, Gecse K, Maaser C, Feagan BG, Wilkens R

Controlled Clinical Trials of IBD Treatment

May 4, 2026

12:30 PM – 1:30 PM CT

McCormick Place - Poster Hall, Level 3, Hall F2

POSTER #Mo1510

Molecular and cellular signatures accompanying early disease clearance in ulcerative colitis patients treated with vedolizumab in the VERDICT trial

Mehandru S (presenting author), Powell N, Silverberg M, Peyrin-Biroulet L, Hernandez Rocha C, Colombel JF, D’Haens G, Moran GW, Sebastian S, Travis S, Filice M, Massimino L, Picard J, Sangiorgi B, Shackelton LM, Smith MI, Teft W, Arunachalam V, Agboton C, Farahmand S, Freire M, Paraskevopoulou M, Panchal P, Wan Y-W, Feagan BG, Jairath V

Omics, Spatial and Systems Biology I

May 4, 2026

12:30 PM – 1:30 PM CT

McCormick Place - Poster Hall, Level 3, Hall F2

POSTER #Mo1475

Gut inflammatory monocytes as biomarkers of treatment response to TYK2 inhibition in inflammatory bowel disease

Onabajo O (presenting author), Tang J, Creed H, Hornsby E, Wyrobnik I, Cogan A, Wilson E, Sherlock J, Wennbo H, Heap G, Arunachalam V, Choudhury A, Lindsay JO, Stagg A

Immune and Non-Immune Cells in Intestinal Inflammation

May 4, 2026

12:30 PM – 1:30 PM CT

McCormick Place - Poster Hall, Level 3, Hall F2

POSTER #Tu1465

Zasocitinib (TAK-279), an investigational oral, allosteric, highly selective and potent TYK2 inhibitor preserves anti-inflammatory IL-10 signaling in vitro

Orlandi C (presenting author), Lin K-Y, Kumar S, Sherlock J, Wilson E, Petrakis I, Salas A

Mechanisms of IBD Therapeutics

May 5, 2026

12:30 PM – 1:30 PM CT

McCormick Place - Poster Hall, Level 3, Hall F2

POSTER #Tu1487

Molecular characterization of responders to vedolizumab identified by symptom response trajectories, study endpoints, and mucosal gene transcriptomic analyses

Paraskevopoulou M (presenting author), Farahmand S, Hou R, Cheng J, Panchal P, Agboton C, Candela N, Yajnik V, Dulai PS, Schreiber S, Thakker P

Omics, Spatial and Systems Biology II

May 5, 2026

12:30 PM – 1:30 PM CT

McCormick Place - Poster Hall, Level 3, Hall F2

POSTER #Tu1494

Machine learning-based stratification to define distinct disease trajectories following advanced therapy initiation in Crohn’s disease and ulcerative colitis

Xiong X, Cai E, Panickan V, Morini Sweet S, Wanchaitanawong W, Duan R, Chou C, Brown J, Sanchirico M, Hughes G, Cai T, Ananthakrishnan A (presenting author)

AI Applications in IBD

May 5, 2026

12:30 PM – 1:30 PM CT

McCormick Place - Poster Hall, Level 3, Hall F2

POSTER #Tu1495

Machine-learning based stratification identifies treatment trajectory subtypes and unmet need in inflammatory bowel diseases

Xiong X, Cai E, Panickan V, Morini Sweet S, Wanchaitanawong W, Duan R, Chou C, Brown J, Sanchirico M, Hughes G, Cai T, Ananthakrishnan A (presenting author)

AI Applications in IBD

May 5, 2026

12:30 PM – 1:30 PM CT

McCormick Place - Poster Hall, Level 3, Hall F2

POSTER #Tu1496

Reclassification and assessment of patients with inflammatory bowel disease: A large language model-based framework for disease activity tracking and trajectory modeling in routine practice

Lin Z (presenting author), Rosas L, Chou C, Brown J, Sanchirico M, Hanauer SB, Luo Y, Dulai PS

AI Applications in IBD

May 5, 2026

12:30 PM – 1:30 PM CT

McCormick Place - Poster Hall, Level 3, Hall F2

date-card-poster

POSTER #Tu1106

Real-world experiences with treatments for eosinophilic esophagitis (EoE) in the USA: Qualitative results from interviews with patients and healthcare professionals

Low EE, Goodwin B, Khoja L, Lloyd J, Houpt B, Daniel I, Schaeffer-Koziol C, Terreri B, Gonsalves N (presenting author)

Eosinophilic Esophagitis: Treatment

May 5, 2026

12:30 PM – 1:30 PM CT

McCormick Place - Poster Hall, Level 3, Hall F2

POSTER #Tu1098

Treatment patterns in patients with eosinophilic esophagitis (EoE) in the USA treated with budesonide oral suspension, off-label corticosteroids and dupilumab

Sauer B (presenting author), McGowan EC, Lam F, Silber A, Goodwin B, Khoja L, Schaeffer-Koziol C, Terreri B, Moawad FJ

Eosinophilic Esophagitis: Treatment

May 5, 2026

12:30 PM – 1:30 PM CT

McCormick Place - Poster Hall, Level 3, Hall F2

date-card-poster

POSTER #Tu1104

Patients receiving budesonide oral suspension (BOS) in real-world practice have more severe eosinophilic esophagitis (EoE) at baseline than those not receiving BOS: Results from a retrospective cohort study using US health insurance claims data

Dellon ES (presenting author), Goodwin B, Lee L, Korgaonkar S, Meyers J, Schaeffer-Koziol C, Terreri B, Shah E

Eosinophilic Esophagitis: Treatment

May 5, 2026

12:30 PM – 1:30 PM CT

McCormick Place - Poster Hall, Level 3, Hall F2

date-card-poster

POSTER #Su1792

Healthcare resource utilization for adults and children with short bowel syndrome-associated intestinal failure identified from ICD-10-CM codes: Real-world US claims analysis

Buchman AL (presenting author), Goodwin B, Iyer KR, Lam F, Liu Y, Mercer DF, Silber A, Terreri B, Tappenden K

Intestinal Failure and Short Gut

May 3, 2026

12:30 PM – 1:30 PM CT

McCormick Place - Poster Hall, Level 3, Hall F2

date-card-poster

POSTER #Sa1254

Meaningful symptom change in celiac disease: Qualitative findings from an exit interview study following a Phase 2 clinical trial

Ghura S (presenting author), Harris N, Arvizu M, Leffler DA

Celiac Disease I

May 2, 2026

12:30 PM – 1:30 PM CT

McCormick Place - Poster Hall, Level 3, Hall F2

POSTER #Sa1253

Psychometric validation of the Celiac Disease Symptom Diary v2.1 using data from a Phase 2 study in patients with moderate to severe celiac disease

Ghura S (presenting author), Rockwood N, Tahir M, Arvizu M, McLeod L, Leffler DA

Celiac Disease I

May 2, 2026

12:30 PM – 1:30 PM CT

McCormick Place - Poster Hall, Level 3, Hall F2

POSTER #Sa1255

Symptom severity and inadvertent gluten exposure among patients with celiac disease

Arvizu M, Marden J, Sethi S, Cheinquer N, Saad R, Ghura S (presenting author), Canavan J, Liu E, Adams DMW, Geller M

Celiac Disease I

May 2, 2026

12:30 PM – 1:30 PM CT

McCormick Place - Poster Hall, Level 3, Hall F2

ePOSTER #146

Risk of eating disorders in patients with celiac disease and their first-degree relatives: A nationwide population-based cohort study

Yao J (presenting author), Sun J, Bergman D, Mårild K, Liu S, Green PHR, Arvizu M, Bulik CM, Lebwohl B, Ludvigsson J

Small Intestine ePoster Showcase

May 2, 2026

1:15 PM – 1:45 PM CT

McCormick Place - Poster Hall, Level 3, Hall F2

ORAL PRESENTATION #1003

Assessing histologic change in serial celiac duodenal biopsies using routine pathology practices: Factors affecting accuracy and interobserver reliability

Robert M (presenting author), Chen ZE, Pacheco C, Goldsmith J, Gonzalez RS, Pai R, Panarelli N, Lagana SM, Arnold M, Wilkins B, Karamchandani DM

Clinical Insights in Celiac Disease

May 5, 2026

8:00 AM – 9:30 AM CT

McCormick Place - W195

ORAL PRESENTATION #1098

TG2 inhibition during gluten reintroduction skews duodenal immunometabolism toward omega-3/linoleic pathways and ferroptosis control in celiac disease

Pesi A (presenting author), Dotsenko V, Isola J, Taavela J, Mohrbacher R, Mueller R, Tewes B, Mäki M, Viiri K, Schuppan D

Celiac Disease: Mechanisms and Endpoints

May 5, 2026

10:00 AM – 11:30 AM CT

McCormick Place - W184d

ORAL PRESENTATION #1099

Continuous composite scoring histologic and biomarker indicators for celiac disease

Syage JA (presenting author), Maxwell J, Lavin PT, Fremgaard Risnes L, Lundin KEA, Sollid LM

Celiac Disease: Mechanisms and Endpoints

May 5, 2026

10:00 AM – 11:30 AM CT

McCormick Place - W184d

date-card-poster

POSTER #Tu1223

Efficacy of potassium-competitive acid blocker (PCAB)-based therapies for  Helicobacter pylori  infection: A network meta-analysis of randomized controlled trials

Mi C, Zhou K, Shi Y, Liang K, Zhou F, Song Z (presenting author)

Helicobacter pylori: Treatment, Antimicrobial Resistance

May 5, 2026

12:30 PM – 1:30 PM CT

McCormick Place - Poster Hall, Level 3, Hall F2

POSTER #Tu1165

Effectiveness and safety of vonoprazan in elderly Chinese patients with gastroesophageal reflux disease: A post hoc analysis of the multicentre, prospective, VIEW study

Xiao Y, Wang B, Xu L, Liang K (presenting author), Zhou F, Chen M

GERD: Medical Treatment

May 5, 2026

12:30 PM – 1:30 PM CT

McCormick Place - Poster Hall, Level 3, Hall F2

date-card-poster

POSTER #Tu1168

Effectiveness of vonoprazan on symptom relief in gastroesophageal reflux disease patients with anxiety or depression in China: Post hoc analysis of the VIEW study

Xiao Y, Hou X, Zhang D, Liang K (presenting author), Zhou F, Chen M

GERD: Medical Treatment

May 5, 2026

12:30 PM – 1:30 PM CT

McCormick Place - Poster Hall, Level 3, Hall F2